Corcept Therapeutics Inc. CORT
Analyst Ratings
- Consensus
- Moderate Buy — 4 Buy · 0 Hold · 1 Sell (5 analysts)
- Avg. Price Target
- $122.60 (+7.1% upside)
Key Stats
- Today's Range
- $110.08 – $114.90
- 50-Day Range
- $72.29 – $122.21
- 52-Week Range
- $28.66 – $122.21
- Volume
- 729K shs
- Average Volume
- 1.24 million shs
- Market Cap
- $12.13 billion
- P/E Ratio
- 131.57
- Dividend Yield
- —
Valuation
- P/E Ratio
- 131.57
- Price / Book
- 19.19
- Price / Sales
- 16.36
Short Interest
- Short Interest
- 16.06%
- Days to Cover
- 4.64
Financials (TTM)
- Revenue
- $741.17 million
- Net Income
- $106.11 million
- Net Margin
- 14.32%
- Return on Equity
- 16.79%
- Debt-to-Equity
- —
About Corcept Therapeutics Inc.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Related Stocks
Compare head-to-head: CORT vs LLY·CORT vs JNJ·CORT vs ABBV·CORT vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.